PSMA has been used as a main target for treating prostate cancer, and it has shown encouraging results when used as radioligand therapy (i.e., 177Lu-PSMA-617 [45]); however, Tagawa et al. [29] concluded that high toxicity followed treatment when it is used as RIT even though it prolonged survival. The gene discussed is FOLH1; the disease is prostate carcinoma.